<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03182335</url>
  </required_header>
  <id_info>
    <org_study_id>15-1532</org_study_id>
    <nct_id>NCT03182335</nct_id>
  </id_info>
  <brief_title>Vasopressor SAT Study</brief_title>
  <official_title>An Assessment of Vasoactive Medication Dose in Mechanically Ventilated Patients Undergoing Daily Sedation Awakening Trial (SAT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the impact of daily awakening from sedation on the amount of vasoactive medication&#xD;
      required in the ICU. The hypothesis of this proposal is that the amount of vasoactive drug&#xD;
      required to maintain an adequate mean arterial blood pressure will be reduced during a daily&#xD;
      awakening from sedation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This observational study will compare mean arterial pressure and vasoactive drug dose&#xD;
      recorded at two time points:&#xD;
&#xD;
        1. prior to awakening from sedation&#xD;
&#xD;
        2. during the awakening from sedation trial The vasoactive infusion will be titrated to a&#xD;
           mean arterial pressure as determined by the medical team prior to study enrollment. Each&#xD;
           enrolled patient will have measurements taken only on the first day of enrollment.&#xD;
           Enrolled subjects will also have a delirium assessment using the CAM-ICU tool before the&#xD;
           awakening from sedation trial and during the awakening from sedation trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change in vasoactive drug dose</measure>
    <time_frame>baseline thru study completion on average &lt; 4 hrs</time_frame>
    <description>mcg/kg/min baseline dose and nadir dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in mean arterial blood pressure</measure>
    <time_frame>baseline thru study completion on average &lt;4 hrs</time_frame>
    <description>mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in prevalence of ICU delirium</measure>
    <time_frame>baseline thru study completion on average &lt;4hrs</time_frame>
    <description>CAM ICU score</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">24</enrollment>
  <condition>Low Blood Pressure</condition>
  <condition>Delirium</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Mechanical Ventilation (MV) with vasoactive infusions</arm_group_label>
    <description>adult ICU patients who are mechanically ventilated with sedative infusion and/or analgesic infusion and also requiring vasoactive drug infusions for the treatment of shock. Patients will be excluded if receiving dexmedetomidine as sedative.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sedation awakening trial</intervention_name>
    <description>vital signs and delirium assessment (CAM-ICU) at baseline then following routine sedation awakening trial. Patient will thus serve as their own control for these interventions</description>
    <arm_group_label>Mechanical Ventilation (MV) with vasoactive infusions</arm_group_label>
    <other_name>SAT</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        adult patients admitted to the intensive care unit&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  requiring Mechanical ventilation through an endotracheal tube with infusion of&#xD;
             sedative or analgesic agent for comfort&#xD;
&#xD;
          -  requiring vasoactive drug via central venous catheter for the treatment of shock&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients receiving Dexmedetomidine as sedative&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Kress, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2017</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

